U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850518) titled 'Magnetic Mitohormesis (MM) Treatment in Stroke Rehabilitation.' on June 24, 2024.
Brief Summary: Although sarcopenia is commonly seen in stroke patients with a prevalence rate of 42%, relevant research studies are more in geriatric population rather than in stroke patients. Beside conventional functional physiotherapy, improving blood circulation, improving cellular oxygenation and reducing inflammation by MM therapy is supposed to improve muscle atrophy after stroke, thus enhancing the functional recovery.
The investigators are not investigating the direct effect of MM therapy on muscle mass in the current study, but are looking at...